STOCK TITAN

Director of C4 Therapeutics (NASDAQ: CCCC) receives 2,650-share stock award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Anderson Kenneth Carl reported acquisition or exercise transactions in this Form 4 filing.

C4 Therapeutics, Inc. director Kenneth C. Anderson received an equity award of common stock rather than cash fees for his board service. On July 1, 2026, he was granted 2,650 shares at a value based on the closing market price of $4.34 per share, in line with the company’s Non-Employee Director Compensation Policy. Following this compensation grant, Anderson directly holds 71,950 common shares. Additional shares are held indirectly through several Anderson family revocable and irrevocable trusts, for which he disclaims beneficial ownership except for any pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Anderson Kenneth Carl
Role null
Type Security Shares Price Value
Grant/Award Common Stock 2,650 $4.34 $12K
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 71,950 shares (Direct, null); Common Stock — 129,877 shares (Indirect, By Kenneth C. Anderson 2021 Irrevocable Trust)
Footnotes (1)
  1. These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2026. Shares held by the Kenneth C. Anderson 2021 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Shares held by the Kenneth C. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Shares held by the Cynthia E. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Shares held by the Kenneth C. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Shares held by the Cynthia E. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Director stock award 2,650 shares Common stock grant as non-employee director compensation on July 1, 2026
Award valuation price $4.34 per share Based on closing market price of common stock on July 1, 2026
Direct holdings after grant 71,950 shares Common stock directly held by Kenneth C. Anderson following the award
Cynthia E. Anderson Revocable Trust holdings 3,623 shares Common stock held indirectly via Cynthia E. Anderson Revocable Trust
Kenneth C. Anderson 2015 Irrevocable Trust holdings 74,581 shares Common stock held indirectly via 2015 Irrevocable Trust
Kenneth C. Anderson 2021 Irrevocable Trust holdings 129,877 shares Common stock held indirectly via 2021 Irrevocable Trust
Non-Employee Director Compensation Policy financial
"issued in accordance with the Issuer's Non-Employee Director Compensation Policy"
Revocable Trust financial
"Shares held by the Kenneth C. Anderson Revocable Trust."
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
Irrevocable Trust financial
"Shares held by the Kenneth C. Anderson 2015 Irrevocable Trust."
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
pecuniary interest financial
"disclaims beneficial ownership of these shares except to the extent of his pecuniary interest"
Grant, award, or other acquisition financial
"transaction_code_description": "Grant, award, or other acquisition""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Anderson Kenneth Carl

(Last)(First)(Middle)
C/O C4 THERAPEUTICS, INC.
490 ARSENAL WAY #120

(Street)
WATERTOWN MASSACHUSETTS 02472

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/01/2026A(1)2,650A$4.34(2)71,950D
Common Stock129,877IBy Kenneth C. Anderson 2021 Irrevocable Trust(3)
Common Stock74,581IBy Kenneth C. Anderson 2015 Irrevocable Trust(4)
Common Stock74,581IBy Cynthia E. Anderson 2015 Irrevocable Trust(5)
Common Stock3,623IBy Kenneth C. Anderson Revocable Trust(6)
Common Stock3,623IBy Cynthia E. Anderson Revocable Trust(7)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2026.
3. Shares held by the Kenneth C. Anderson 2021 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
4. Shares held by the Kenneth C. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
5. Shares held by the Cynthia E. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
6. Shares held by the Kenneth C. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
7. Shares held by the Cynthia E. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Remarks:
/s/ Shagha Russell, Attorney-in-Fact07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did C4 Therapeutics (CCCC) director Kenneth C. Anderson report in this Form 4?

Kenneth C. Anderson reported receiving an award of 2,650 shares of C4 Therapeutics common stock. The shares were issued as compensation for his service as a non-employee director, in place of a cash fee, under the company’s director compensation policy.

At what price were the awarded C4 Therapeutics (CCCC) shares valued for Kenneth C. Anderson?

The 2,650 awarded shares were valued at $4.34 per share. This price was based on the closing market price of C4 Therapeutics’ common stock on July 1, 2026, as specified in the Form 4 footnotes.

How many C4 Therapeutics (CCCC) shares does Kenneth C. Anderson hold directly after this Form 4 transaction?

After the reported award, Kenneth C. Anderson directly holds 71,950 shares of C4 Therapeutics common stock. This direct holding figure comes from the post-transaction balance shown for the non-derivative grant on the Form 4.

Why did Kenneth C. Anderson receive C4 Therapeutics (CCCC) shares instead of cash?

He elected to receive shares instead of cash under C4 Therapeutics’ Non-Employee Director Compensation Policy. The filing notes he chose stock in lieu of cash compensation for his services as a non-employee director of the company.

Does this C4 Therapeutics (CCCC) Form 4 show any open-market purchases or sales by Kenneth C. Anderson?

The Form 4 does not show open-market purchases or sales. It reports a grant of 2,650 shares as director compensation and multiple trust holdings entries, with no transactions coded as open-market buys or sells.